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Purpose: To report the therapeutic efﬁcacy and results of an accidentally injected intralenticular
sustained-release dexamethasone implant (Ozurdex) in a patient with macular edema secondary to
central retinal vein occlusion at 14 months after injection.
Observations: We present a 70-year-old female patient with central retinal vein occlusion who un-
derwent an Ozurdex injection. Patient discontinued from the treatment period during the 14-month
and there was no ophthalmologic examination of the patient. Detailed ophthalmological examination
was performed. Ozurdex localization was determined by Pentacam rotating Scheimpﬂug System. The
implant was accidentally injected into the crystalline lens. It did not cause a totally lens opaciﬁcation
but did result only in a posterior subcapsular cataract. The macular edema did not resolve, and the
patient underwent phacoemulsiﬁcation surgery.
Conclusions and importance: Ozurdex that totally located inside the crystallize lens may not have the
therapeutic effects.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The dexamethasone implant (Ozurdex®; Allergan Inc., Irvine,
CA, USA) is a potent anti-inﬂammatory agent that reduces macula
edema following retinal vein occlusion (RVO) by preventing
leukocyte migration and proinﬂammatory cytokines, stabilizing
endothelial cell tight junctions, inhibiting synthesis of vascular
endothelial growth factor.1 Ozurdex is associated with ocular side
effects such as cataracts, glaucoma, endopthalmitis, conjunctival
hemorrhage and retinal detachment.2 Rarely has it been shown to
be accidentally injected intralenticularly for sustained release of
dexamethasone implant.
Here, we report a rare complication of Ozurdex implant that was
completely embedded into the phakic lens that did not resolve
macular edema.
2. Case report
A 70-year-old female patient presented with blurred vision
and a shadow in front of the right eye. She had hypertension andology, Kayseri Education and
askan).
Inc. This is an open access article uhyperlipidemia that were medically controlled. On examination,
visual acuity was ﬁnger counting at 2 m in the right eye and 20/
40 in the left eye. Intraocular pressures were normal. Slit-lamp
examination and pentacam showed that the implant had totally
penetrated in the crystalized lens and posterior cortical cataract
(Fig. 1). Dilated fundus examination revealed a hyperemic and
blurred disc. There were generalized dilatation and increased
tortuosity in retinal veins, multiple dot and blot hemorrhages in
all four quadrants. Optical coherence tomography showed cys-
toid macular edema with a central retinal thickness of 810 mm
(Fig. 2A).
The previous fundus ﬂuorescein angiography showed non-
ischemic CRVO and macular edema in right eye before the acci-
dental intralenticular injection of sustained-release dexametha-
sone implant. Since 14 months, there was no ophthalmologic
examination of the patient. There was no deformation in the
length, form of the implant and also central retinal thickness was
unchanged compared to measurement immediate before the
injection (Fig. 2B). IOP was within normal limits. The patient
underwent phacoemulsiﬁcation surgery at 14 months after the
injection. In the phacoemulsiﬁcation Ozurdex was divided with
the crystalline lens and aspirated with phacoemulsiﬁcation
probe. After nucleus removal, the posterior capsule rupture had
occurred during surgery, and a three-piece intraocular lens (IOL)nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Slit-lamp photograph and Pentacam scan of the crystalline lens showing Intralenticular dexamethasone implant.
Fig. 2. Optical coherence tomography of the right eye. A. Before the injection. B. Central retinal thickness was unchanged after the 14 months. C. After 2 weeks of phacoemul-
siﬁcation surgery.
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injected into the vitreous cavity at the end of surgery. On the ﬁrst
postoperative day, the IOL was well centered with a no anterior
chamber reaction. Macular thickness increased in OCT that was
taken after 2 weeks of phacoemulsiﬁcation surgery (945 mm,
Fig. 2C). We believe that this increased the macular edema
caused by surgery. Visual acuity 1 month after surgery was 20/
200 and decreased cystoid macular edema with a central retinal
thickness of 560 mm.
3. Discussion
Accidental injection of sustained-release intravitreal dexa-
methasone implant into the crystalline lens is a rare complication.
The therapeutic effect of intralenticular Ozurdex is controversial.
There are a few case reports about this complication.3e5 These case
reports have shown that inadvertent injection of Ozurdex implant
can solve macular edema. They recommend that the authors
describe a positive outcome about the therapeutic efﬁcacy of an
accidentally injected intralenticular sustained-release dexametha-
sone implant.
Sekeroglu et al. reported one case that inadvertently injected
sustained-release intravitreal dexamethasone implant into the
crystalline lens. In their case, the implant was partially in the lens
capsule and partially in the vitreous. The patient was underwent
phacoemulsiﬁcation surgery at 7 months after injection.3 Chhabra
et al. reported a case of accidental insertion of dexamethasone
implant into the crystalline lens. After 3 months when there was a
remarkable improvement in macular edema and visual acuity
they performed phacoemulsiﬁcation with removal of the implant.
These case reports described that the therapeutic efﬁcacy and
resolving the macular edema of inadvertently injected intra-
lenticular Ozurdex.4 Chalioulias et al. described a differentmanagement scheme than Chhabra. They performed early surgi-
cal intervention because of cataract and inability to visualise the
fundus.5 Chalioulias et al. has followed the patient for two weeks
and then changed the location of the implant into the vitreous.
Ozurdex implant normally dissolves completely within 6
months to release dexamethasone5 but in our patient Ozurdex
remained with minimal changes the structure for 14 months.
Possibility of posterior capsular ﬁbrosis or intralenticuler locali-
zation might affect the dissolution of Ozurdex. Furthermore
inadequate contact with the vitreous of Ozurdex might lead to
unsatisfactory therapeutic efﬁcacy although subretinal ﬂuid and
total volume was nearly reduced.
Once inadvertent injection of Ozurdex into the crystalline lens
occurs, the clinical management strategy might be based on
directly contact with the vitreous or position of the implant into the
crystalline lens. So that we recommend the clinical decision to
observe or early operation of intralenticular Ozurdex should be
individualized.
In conclusion, ophthalmologists should pay attention during
the application of Ozurdex implant. Ozurdex that located totally
inside the crystallize lens may not have the therapeutic effects.4. Patient consent
The patient provided written consent for publication of this case
report.
Including medical record details and photographs.References
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